We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
Cap. Flow
+$201M
Cap. Flow %
50.06%
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.5M
3
NUVL
Nuvalent
NUVL
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$12.7M
5
ALKS icon
Alkermes
ALKS
+$10.6M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$15.8M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$14M
3
APLT
Applied Therapeutics
APLT
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$9.5M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$2.02B
$38M 9.48%
2,872,601
+1,141,410
+66% +$19.5M
ROIV icon
2
Roivant Sciences
ROIV
$24.8B
$32.1M 8.01%
2,712,778
-57,041
-2% -$674K
IMVT icon
3
Immunovant
IMVT
$8.27B
$27.7M 6.92%
1,118,508
+447,507
+67% +$12.7M
MRUS
4
DELISTED
Merus
MRUS
$25.9M 6.45%
614,812
+193,590
+46% +$9.3M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.88B
$16.2M 4.05%
317,060
+103,245
+48% +$5.78M
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.6B
$14.7M 3.68%
+375,845
New +$15.5M
INCY icon
7
Incyte
INCY
$23.4B
$13.4M 3.34%
193,623
+64,133
+50% +$4.57M
ALKS icon
8
Alkermes
ALKS
$8.79B
$12M 2.99%
416,968
+368,050
+752% +$10.6M
DNLI icon
9
Denali Therapeutics
DNLI
$3.7B
$11.9M 2.97%
584,328
+302,278
+107% +$7.74M
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$7.31B
$11.6M 2.91%
208,016
+166,748
+404% +$9.21M
NUVL
11
DELISTED
Nuvalent
NUVL
$11.4M 2.84%
+145,234
New +$13.6M
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$10.8M 2.68%
641,964
+558,302
+667% +$9.25M
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.77B
$10.3M 2.58%
134,178
-39,856
-23% -$2.88M
BMY icon
14
Bristol-Myers Squibb
BMY
$124B
$9.39M 2.34%
166,068
-109,235
-40% -$6.1M
WVE icon
15
Wave Life Sciences
WVE
$1.12B
$8.92M 2.23%
721,209
+421,209
+140% +$5.62M
RVMD icon
16
Revolution Medicines
RVMD
$39.6B
$8.47M 2.11%
193,535
+176,881
+1,062% +$8.93M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$8.41M 2.1%
+992,803
New +$10.3M
JANX icon
18
Janux Therapeutics
JANX
$992M
$7.81M 1.95%
145,876
+96,461
+195% +$5.1M
INSM icon
19
Insmed
INSM
$23.5B
$7.36M 1.84%
+106,610
New +$7.68M
SRRK icon
20
Scholar Rock
SRRK
$6.33B
$7.19M 1.79%
+166,307
New +$5.42M
IOVA icon
21
Iovance Biotherapeutics
IOVA
$2.23B
$7.03M 1.75%
+949,401
New +$8.8M
BNTX icon
22
BioNTech
BNTX
$23.1B
$7M 1.75%
+61,403
New +$7.01M
ARQT icon
23
Arcutis Biotherapeutics
ARQT
$3.56B
$6.98M 1.74%
500,966
-1,277,352
-72% -$14M
BHVN icon
24
Biohaven
BHVN
$2.32B
$6.96M 1.74%
186,413
-30,027
-14% -$1.4M
VTGN icon
25
VistaGen Therapeutics
VTGN
$9.4M
$5.95M 1.48%
2,328,492
+481,700
+26% +$1.36M
1
2 3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $201M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.

  • Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
  • Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
  • Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
  • Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
  • Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
  • Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
  • Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.